Biosynthetic corneas: prospects for supplementing the human donor cornea supply

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

Patents relating to the production of human-source collagen used in biosynthetic corneas implanted into patients are owned by FibroGen Inc. and are used under license. A patent application related to the formulation of the biomaterials described has been filed and assigned to the Ottawa Hospital Research Institute and is currently licenced to Eyegenix Inc., a wholly-owned subsidiary of Cellular Bioengineering Inc., for use in corneal transplantation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.